145 related articles for article (PubMed ID: 1520318)
1. Metabolic studies in a mouse model of hepatorenal tyrosinemia: absence of perinatal abnormalities.
Collins JC; Buchanan DN; Thoene JG; Erickson RP; Brooks SS; Gluecksohn-Waelsch S
Biochem Biophys Res Commun; 1992 Aug; 187(1):340-6. PubMed ID: 1520318
[TBL] [Abstract][Full Text] [Related]
2. Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1.
Kelsey G; Ruppert S; Beermann F; Grund C; Tanguay RM; Schütz G
Genes Dev; 1993 Dec; 7(12A):2285-97. PubMed ID: 8253377
[TBL] [Abstract][Full Text] [Related]
3. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of fumarylacetoacetase without hereditary tyrosinemia.
Kvittingen EA; Børresen AL; Stokke O; van der Hagen CB; Lie SO
Clin Genet; 1985 Jun; 27(6):550-4. PubMed ID: 4017276
[TBL] [Abstract][Full Text] [Related]
5. Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus.
Klebig ML; Russell LB; Rinchik EM
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1363-7. PubMed ID: 1741389
[TBL] [Abstract][Full Text] [Related]
6. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice.
Ruppert S; Kelsey G; Schedl A; Schmid E; Thies E; Schütz G
Genes Dev; 1992 Aug; 6(8):1430-43. PubMed ID: 1644288
[TBL] [Abstract][Full Text] [Related]
8. Hereditary tyrosinemia type I--an overview.
Kvittingen EA
Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
[TBL] [Abstract][Full Text] [Related]
9. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway.
Endo F; Kubo S; Awata H; Kiwaki K; Katoh H; Kanegae Y; Saito I; Miyazaki J; Yamamoto T; Jakobs C; Hattori S; Matsuda I
J Biol Chem; 1997 Sep; 272(39):24426-32. PubMed ID: 9305902
[TBL] [Abstract][Full Text] [Related]
10. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.
Blackburn PR; Hickey RD; Nace RA; Giama NH; Kraft DL; Bordner AJ; Chaiteerakij R; McCormick JB; Radulovic M; Graham RP; Torbenson MS; Tortorelli S; Scott CR; Lindor NM; Milliner DS; Oglesbee D; Al-Qabandi W; Grompe M; Gavrilov DK; El-Youssef M; Clark KJ; Atwal PS; Roberts LR; Klee EW; Ekker SC
Hum Mutat; 2016 Oct; 37(10):1097-105. PubMed ID: 27397503
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.
Bergman AJ; van den Berg IE; Brink W; Poll-The BT; Ploos van Amstel JK; Berger R
Hum Mutat; 1998; 12(1):19-26. PubMed ID: 9633815
[TBL] [Abstract][Full Text] [Related]
12. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase.
Kvittingen EA; Brodtkorb E
Scand J Clin Lab Invest Suppl; 1986; 184():35-40. PubMed ID: 3473612
[TBL] [Abstract][Full Text] [Related]
13. Identification of a combined missense/splice-site mutation in FAH causing tyrosinemia type 1.
Haghighi-Kakhki H; Rezazadeh J; Ahmadi-Shadmehri A
J Pediatr Endocrinol Metab; 2014 Jul; 27(7-8):795-8. PubMed ID: 24756054
[TBL] [Abstract][Full Text] [Related]
14. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.
St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM
Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054
[TBL] [Abstract][Full Text] [Related]
15. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
[TBL] [Abstract][Full Text] [Related]
16. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M
Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview.
St-Louis M; Tanguay RM
Hum Mutat; 1997; 9(4):291-9. PubMed ID: 9101289
[TBL] [Abstract][Full Text] [Related]
19. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice.
Sun MS; Hattori S; Kubo S; Awata H; Matsuda I; Endo F
J Am Soc Nephrol; 2000 Feb; 11(2):291-300. PubMed ID: 10665936
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I.
Grompe M; al-Dhalimy M
Hum Mutat; 1993; 2(2):85-93. PubMed ID: 8318997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]